NEUROBIOLOGY OF AGING | 卷:48 |
Major amyloid-β-degrading enzymes, endothelin-converting enzyme-2 and neprilysin, are expressed by distinct populations of GABAergic interneurons in hippocampus and neocortex | |
Article | |
Pacheco-Quinto, Javier1,2  Eckman, Christopher B.1,2  Eckman, Elizabeth A.1,2  | |
[1] Atlantic Hlth Syst, Morristown, NJ USA | |
[2] Biomed Res Inst New Jersey, 140 East Hanover Ave, Cedar Knolls, NJ 07927 USA | |
关键词: Alzheimer's disease; A beta degradation; Endothelin-converting enzyme; GABA; Interneuron; Neprilysin; Somatostatin; Parvalbumin; | |
DOI : 10.1016/j.neurobiolaging.2016.08.011 | |
来源: Elsevier | |
【 摘 要 】
Impaired clearance of amyloid-beta peptide (A beta) has been postulated to significantly contribute to the amyloid accumulation typical of Alzheimer's disease. Among the enzymes known to degrade A beta in vivo are endothelin-converting enzyme (ECE)-1, ECE-2, and neprilysin (NEP), and evidence suggests that they regulate independent pools of A beta that may be functionally significant. To better understand the differential regulation of A beta concentration by its physiological degrading enzymes, we characterized the cell and region-specific expression pattern of ECE-1, ECE-2, and NEP by in situ hybridization and immunohistochemistry in brain areas relevant to Alzheimer's disease. In contrast to the broader distribution of ECE-1, ECE-2 and NEP were found enriched in GABAergic neurons. ECE-2 was majorly expressed by somatostatin-expressing interneurons and was active in isolated synaptosomes. NEP messenger RNA was found mainly in parvalbumin-expressing interneurons, with NEP protein localized to perisomatic par-valbuminergic synapses. The identification of somatostatinergic and parvalbuminergic synapses as hubs for A beta degradation is consistent with the possibility that A beta may have a physiological function related to the regulation of inhibitory signaling. (C) 2016 Elsevier Inc. All rights reserved.
【 授权许可】
Free
【 预 览 】
Files | Size | Format | View |
---|---|---|---|
10_1016_j_neurobiolaging_2016_08_011.pdf | 5490KB | download |